RESEARCH TRIANGLE PARK, N.C - Thursday, October 31st 2013 [ME NewsWire]
(BUSINESS
WIRE) Quintiles today announced that John Ratliff has resigned his
position as president and chief operating officer (COO) effective
December 31, 2013. He has also resigned his role as a member of the
Quintiles Transnational Holdings Inc. board of directors.
“On
behalf of our board of directors, senior Quintiles management team and
our employees around the world, I would like to thank John Ratliff for
his leadership and tireless dedication to Quintiles over the past nine
years,” said CEO Tom Pike. “Quintiles is known for its strong management
team, and I’m confident that these executives will ensure a smooth
transition for our customers, employees and the patients we ultimately
serve. John helped to grow this team as Quintiles has grown. We wish him
well in his future endeavors.”
Ratliff joined Quintiles as chief
financial officer in 2004, shortly after the company began its
transition from public to private ownership in 2003. In 2006, he was
named chief operating officer and was appointed to Quintiles’ board.
“Quintiles
is a special company where I have had a tremendous experience, both
professionally and personally for almost a decade,” Ratliff said. “The
difference this company has made in people’s lives is truly amazing, and
I am extremely proud to have played a part in it. I love Quintiles and
wish the best of luck to the entire organization,” Ratliff concluded.
About Quintiles
Quintiles
(NYSE: Q) is the world’s largest provider of biopharmaceutical
development and commercial outsourcing services with a network of more
than 28,000 employees conducting business in approximately 100
countries. We have helped develop or commercialize all of the top-50
best-selling drugs on the market. Quintiles applies the breadth and
depth of our service offerings along with extensive therapeutic,
scientific and analytics expertise to help our customers navigate an
increasingly complex healthcare environment as they seek to improve
efficiency and effectiveness in the delivery of better healthcare
outcomes. To learn more about Quintiles, please visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.
Contacts
Quintiles
Phil Bridges, + 1-919-998-1653
Media Relations
phil.bridges@quintiles.com
Mobile: +1-919-457-6347
Karl Deonanan, +1-919-998-2789
Investor Relations
InvestorRelations@quintiles.com
Permalink: http://www.me-newswire.net/news/9039/en
No comments:
Post a Comment